Оптимизация режимов лечения больных бластным кризом хронического миелолейкоза с учетом лекарственной чувствительности бластных клеток in vitro
![Диссертация: Оптимизация режимов лечения больных бластным кризом хронического миелолейкоза с учетом лекарственной чувствительности бластных клеток in vitro](https://westud.ru/work/5199148/cover.png)
Диссертация
Работа осуществлялась в период с июля 1996 г. по май 2002 г. на базе отделения химиотерапии лейкозов и патологии эритрона (научный руководитель — проф., д.м.н. Н.Д.Хорошко) Гематологического Научного Центра Российской Академии Медицинских Наук (далее — ГНЦ РАМН, директор — академик РАМН и РАН, профессор А.И.Воробьев). Вариант БК устанавливался у всех больных до начала лечения с помощью… Читать ещё >
Содержание
- Список сокращений
- ГЛАВА 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Молекулярный патогенез хронического миелолейкоза
- 1. 2. Предполагаемые механизмы развития терминальной стадии хронического миелолейкоза
- 1. 2. 1. Значение мутаций генар
- 1. 2. 2. Амплификация онкогена BCR-ABL как возможный механизм развития лекарственной резистентности при хроническом миелолейкозе
- 1. 2. 3. Активация онкогена MYC
- 1. 2. 4. Клеточная резистентность, обусловленная точечными мутациями домена ABL
- 1. 2. 5. Фармакокинетическая резистентность при бластном кризе хронического миелолейкоза
- 1. 3. Исследования устойчивости к цитостатическим препаратам in vitro
- 1. 3. 1. Основные методы исследования лекарственной устойчивости in vitro
- 1. 3. 2. Прогностическая значимость исследований лекарственной устойчивости in vitro при лейкозах
- 1. 3. 3. Индивидуализация химиотерапии по результатам исследования лекарственной устойчивости in vitro
- 1. 3. 4. Исследование лекарственных взаимодействий с помощью тестов in vitro
- 1. 4. Современные подходы к терапии бластного криза хронического миелолейкоза
- ГЛАВА 2. ПАЦИЕНТЫ И МЕТОДЫ ИССЛЕДОВАНИЯ
- 2. 1. Характеристика больных
- 2. 1. 1. Описание исследования
- 2. 2. Методы исследования
- 2. 2. 1. Цитохимические методы
- 2. 2. 2. Иммунологические исследования
- 2. 2. 3. Методы исследования лекарственной чувствительности бластных клеток при бластном кризе хронического миелолейкоза in vitro
- 2. 2. 4. Цитогенетические исследования
- 2. 3. Статистический анализ результатов исследования
- 2. 1. Характеристика больных
- ГЛАВА 3. РЕЗУЛЬТАТЫ СОБСТВЕННЫХ ИССЛЕДОВАНИЙ
- 3. 1. Клинико-гематологическаяхарактеристика больных
- 3. 2. Сравнительная характеристика цитохимического и иммунологического вариантов бластного криза хронического миелолейкоза
- 3. 3. Характеристика лекарственной чувствительности бластных клеток у больных с бластным кризом хронического миелолейкоза in vitro
- 3. 4. Результаты терапии больных бластным кризом хронического миелолейкоза
- 3. 4. 1. Эффективность индукционной терапии больных бластным кризом хронического миелолейкоза с помощью иматиниб мезилата
- 3. 4. 2. Анализ результатов лечения больных бластным кризом хронического миелолейкоза с помощью иматиниб мезилата
- 3. 4. 3. Анализ результатов лечения больных бластным кризом хронического миелолейкоза с помощью полихимиотерапии
- 3. 5. Результаты цитогенетических исследований
- 3. 5. 1. Результаты цитогенетических исследований до начала терапии
- 3. 5. 2. Результаты цитогенетических исследований после проведенного лечения
- 3. 6. Выживаемость
- 3. 6. 1. Выживаемость больных с лимфоидным вариантом бластного криза хронического миелолейкоза
- 3. 6. 2. Выживаемость больных с нелимфоидным вариантом бластного криза хронического миелолейкоза
- 3. 7. Токсичность терапии
Список литературы
- Abrahamson S.L., Lee J.M., Bernstein A. Regulation of p53-mediatedapoptosis and cell cycle arrest by steel factor. Mol. Cell. Biol., 1995, 69 536 960.
- Agthe A.G., Dorffel W., Neuendank A., Hartmann R., Bruhmuller S., Klumper
- E., Pieters R., Veerman A.J.P., Henze G. Tailored therapy for relapsed or refractory childhood acute lymphoblastic leukemia. In Drug Resistance in Leukemia and Lymphoma II, 1997, 51−58, Harwood Acad. Publ., UK.
- Askew D.S., Ashmun R.A., Simmons B.C., Cleveland J.L. Constitutive c-mycexpression in an IL-3-dependent cell line suppresses cell cycle arrest and accelerated apoptosis. Oncogene 1991- 6: 1915−1922.
- Barone S., Baer M.R., Sait S.N., Lawrence D., Block A.W., Wetzler M. Highdose cytsine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. Am J Hematol 2001- 67(2): 119−124.
- Bedi A., Barber J.P., Bedi G.C., el-Deiry W.S., Sidransky D., Vala M.S.,
- Akhtar A.J., Hilton J., Jones R.J. BCR-ABL-mediated apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995- 86: 1148−1158.
- Bedi A., Zenbauer B.A., Barber J.P., Sharkis S.J., Jones R.J. Inhibition ofapoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994- 83: 2038−2044.
- Bellamy C.O. p53 and apoptosis. Br Med Bull 1997- 53: 522−538.
- Bird M.C., Bosanquet A.G., Forskitt S., Gilby E.D. Long-term comparison ofresults of a drug sensitivity assay in vitro with patient response in lymphatic neoplasms. Cancer 1988- 61: 1104−1109.
- Bird M.C., Bosanquet A.G., Forskitt S., Gilby E.D. Semi-micro adaptation of a4. day differential staining cytotoxicity (DiSC) assay for determining the invitro chemosensitivity of haeraatological malignancies. Leuk Res 1986- 10: 445−449.
- Bird M.C., Forskitt S" Gilby E.D., Bosanquet A.G. The influence of sample source and cell concentrations on the in vitro chemosensitivity of haematological tumors. Br J Cancer 1986- 53: 539−545.
- Bird M.C., Godwin V.A.J., Antrobus J.H., Bosanquet A.G. Comparison of in vitro drug sensitivity by the differential staining cytotoxicity (DiSC) and colony-forming assays. Br J Cancer 1987- 55: 429−431.
- Black M.M., Speer F.D. Further observations on the effects of cancer chemotherapeutic agents on the in vitro dehydrogenase activity of cancer tissue. J Natl Cancer Inst 1954- 14: 1147−1158.
- Blandino G., Scardigli R, Rizzo M.G., Crescenci M., Soddu S., Sacchi A., Wild-type p53 modulates apoptosis of normal IL-3 deprived hematopoietic cells. Oncogene, 1995, 10, 731−737.
- Bosanquet A.G. Correlations between therapeutic responce of leukaemias and in vitro drug-sensitivity assay. Lancet 1991- 337: 711−714.
- Bosanquet A.G. In vitro determination of tumor chemosensitivity in haematological malignancies. Haematol Oncol 1985- 3: 1−10.
- Bosanquet A.G., Johnson S.A., Richards S.M. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br. J Haematol. 1999- 106 (1): 71−77.
- Buchner T., Hiddemann G., Loffler H., Nowrousian M., Maschmeyer G.,
- Aul C., Straif K., Hossfeld D., Heinecke A. Double induction by repeating versus alternating regimens versus conventional induction in acute myeloid leukemia (AML). ProcofASCO 1991- 10: 127a.
- Cancer therapy Evaluation Program. Common Toxicity criteria. Bethesda, Md.: National Cancer Institute, March 1998.
- Carmichael J., DeGralf W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomatic colorimetric assay: assesment of chemosensitivity testing. Cancer Res 1987- 47: 936−942.
- Chaudhary P.M., Roninson I.B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J.Natl.Cancer Inst, 1993, 85: 632−639.
- Chervenick P.A., Ellis L.D., Pan S.F., Lawson A.L. Human leukemic cells: in vitro growth of colonies containing the Philadelphia chromosome. Science 1971- 174: 1134−1136.
- Chin K.V., Ueda K., Pastan I., Gottesman M.M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science, 1992, 255,459−462.
- Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H. Thymocyte apoptosis is induced by p53-dependent and independent pathways. Nature, 1993, 362, 849−852.
- Cote R.J., Esrig D., Groshen S., Jones P.A., Skinner D.G. p53 and treatment of bladder cancer. Nature 1997- 385: 123−125.
- Courtenay V.D. A replenishable soft agar colony assay for human tumor sensitivity testing. Resent results in Cancer Res 1984- 94: 17−34.
- Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990- 247: 824−830.
- Dieninger M.W., Goldman J.M., Melo J.V. The molecular biology ofchronic myeloid leukemia. Blood 2000- 96: 3343−3356.
- Dittmer D, Pati S., Zambetti G., Chu S., Teresky A.K., Moore M., Finlay C., Levine A.J. Gain of function mutations in p53. Nat. Genet., 1993, 4, 4246.
- Donehower L.A., Harvey M., Slagle B.L., Mcarthur M.J., Montgomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356, 215−221.
- Druker B. STI571: a paradigm for clinical trials of molecularly targeted agents. EHA-6 Educational Book 2001- Jun: 135−140. Editors: Montserrat E., Mannucci P., Bacigalupo A.
- Dutcher J.P., Lee S., Paietta E., Bennett J.M., Stewart J.A., Wiernik P.H. Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992. Leukemia 1998- 12(7): 1037−1040.
- Evan G.I., Wylie A.H., Gilbert C.S. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 1992- 69: 119−128.
- Fan S., el-Deiry W.S., Bae I., Freeman J., Jondle D., Bhatia K. p53 gene mutations are assosiated with decreased sensitivity of human lymphomacells to DNA damaging agents. Cancer Res 1994- 54: 5821−5830.
- Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990−61:759−767.
- Flaman J.M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappuis P. A simple p53 functional assay for screening cell lines, blood and tumors. Proc Natl Acad Sci 1995- 92: 3963−3967.
- Gale R.P. Chronic myelogenous leukemia: molecule to man. Henry Ford Hosp., Med. J., 1991, vol.39, N.2, pp.108 111.
- Gambacorti-Passerini C., Barni R., le Coutre P. Role of alpha 1 acid glycoprotein inthe in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571. J. Natl Cancer Inst. 2000- 92: 1641−1650.
- Gambacorti-Passerini C., le Coutre P., Mologni L., Fanelli M., Bertazzoli C., Marchesi E. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997- 23: 380−394.
- Giles F.J., Kantarjian H.M., Cortes J., Thomas D.A., Talpaz M., Manshouri T., Albitar M. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance. Cancer, 1999- Sepl- 86(5): 805 813.
- Giralt S., Kantarjian H., Talpaz M. The natural history of chronic myelogenous leukemia in the interferon era. Semin. Hematol. 1995- 32: 152−158.
- Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N.,
- Sawyers C.L. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Sciencexpress 2001- Jun: 1−10.
- Gottlieb T.M., Oren M. p53 in growth control and neoplasia. Biochimica and Biophysica Acta 1996- 1287: 77−102.
- Greenblatt M.S., Bennet W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer ethiology and molecular pathogenesis. Cancer Res., 1995, 54, 4855−4878.
- Griesshammer M., Heinze B., Bangerter M., Heimpel H., Fliedner T.M. Karyotype abnormalities and their clinical significance in blast crisis ofv chronic myeloid leukemia. J Mol Med 1997, 75: 836−838.
- Griesshammer M., Heinze B., Hehlmann A., Popp C., Anger B., Heil G., Bangerter M., Heimpel H. Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients. Ann Hematol 1996- 73:225−230.
- Harker WG, Ward JH, Stewart JR. Principles of therapy and effects of specific drugs in the treatment of neoplastic diseases of the hematopoietic system. Wintrobe’s clinical hematology. Philadelphia. London. 1993.
- Heisterkamp N., Jenster G., ten Hoeve J., Zovich D., Pattengale P.K., Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990- 344: 251−251.
- Hernandes-Boluda J.C., Cervantes F., Costa D., Carrio A., Montserrat E. Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature. Leuk Lymphoma 2000- 38(1−2): 83−90.
- Herzog C.E., Tsokos M., Bates S.E., Fojo A.T. Increased mdr-l/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J. Biol. Chem., 1993- 268: 2946−2952.
- Hill B.T., Whelan R.H., Hurst H.C., McClean S. Identification of adistinctive P-glycoprotein mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated X-irradiation. Cancer, 1994- 73: 2990−2999.
- Hongo T., Fujii Y., Yajima S. In vitro chemosensitivity of childhood leukemic cells nd the clinical value of assay directed chemotherapy. In Drug Resistance in Leukemia and Lymphoma I, 1993, 313−319, Harwood Acad. Publ., UK.
- Hongo T., Yajima S., Sakurai M., Horikoshi Y., Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997- Vol.89 No.8: 29 592 965.
- Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000- 24: 57−60.
- Imamura J., Miyoshi I., Koeffler H.P. p53 in hematological malignancies. Blood 1994- 84:2412−2421.
- Jacquemier J., Moles J.P., Penault-Llorca F., Adelaide J., Torrente M.,
- Viens P. P53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994- 69: 846−852.
- Janossy G., Woodruff R.K., Paxton A. Relation of lymphoid phenotype and response to chemothreapy incorporeting vincristine prednisolone in the acute phase of Ph'-positive leukemia. Cancer, 1986: vol.49 pp.426 — 434.
- Janus F., Albrechtsen N., Dornreiter L., Wiesmuller L., Grosse F., Deppert W. The dual role model for p53 in maintaining genomic integrity. Cell Mol Life Sci 1999- 55: 12−27.
- Johnston J.B., Daeninck P., Verburg L., Lee K., Williams G., Israels L.G., Mowat M.R., Begleiter A. p53, MDM2, Bax and Bcl-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997- 26 (5−6): 435 449.
- Kantarjian H.M., Keating M.J., Talpaz M., Walters R.S., Smith T.L., Cork A., McCredie K.B., Freireich E.J. Chronic myelogenous leukemia in blast crisis. The Am. J. of Med. 1987- 83: 445−454.
- Kantarjian H.M., O’Brien S. M, Keating M., Beran M., Estey E., Giralt S., Kornblau S., Rios M.B., de Vos D., Talpaz M. Results of decitabinetherapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997- 11(10): 1617−1620).
- Kelliher M.A., McLaughlin J., Witte O.N., Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990- 87: 6649−6653.
- Kramer A., Loffler H., Bergmann J., Hochhaus A., Hehlmann R. ProHferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia. Leukemia 2001, 15(1): 62−68.
- Krystal G.W. Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Blood 2002, May 1- 99(9): 3472−3475.
- Lambertenghi-Deliliers G., Annaloro G., Cortellaro M. Idarubicini in blastic crisis of chronic myelogenous leukemia. Hematologica 1991-vol.76: n.5, pp. 406−408.
- Licht T., Fiebig H., Bross K.J., Friedhelm H" Berger D.P., Shoemaker R. Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int. J. Cancer, 1991- 49: 630−637.
- Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E. p53 status and the efficacy of cancer therapy in vivo. Science 1994- 266: 807−810.
- Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990,247: 1079−1082.
- Lundsberg A.S., Weinberg R.A. Control of the cell cycle and apoptosis. Eur J of Cancer 1999- Vol.35, No.4: 531−539.
- Luzzato L., Melo J. Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells. Blood 2002, Aug 15- 100(3): 1105−1106.
- M.Y.Gordon, J.M.Goldman. Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Br. J. of Haematology 1996- 95: 10−20.
- McGahon A., Bissonnette R., Schmitt M., Gotter K.M., Green D.R., Cotter T.G. BCR-ABL maintains resistance of chronic myeloid leukemia cells to apoptotic cell death. Blood 1994- 83: 1179−1187.
- Miyashita T., Krajewsky S., Krajewska M., Wang H.G., Lin HK, Liberman D.A., Hoffman B., Reed J.C. Tumor supressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 1994- 9. 1799−1805.
- Miyazaki M., Kochno K., Uchiyumi T. Activation of human multidrug resistance-1 gene promoter in response to heat shock stress. Biochem Biophys. Res. Commun., 1992- 187: 677−684.
- Montefusco E., Petti M.C., Alimena G., Latagliata R., Celesti F., Capria S.,
- Amadori S., Awisati G., Mandelli F. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia. Ann Oncol 1997- 8(2): 175−179.
- Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 1983- 65: 55−63.
- Nishii K., Kabarowski J.H., Gibbons D.L. BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 1996- 13: 2225−2234.
- Norgaard J.M., Jensen P.D., Bendix K., Clausen N., Palshof T. Relevance of in vitro leukaemia cell survival to short- and long-term clinical outcome in AML. Leuk Lymphoma, 1999- 32 (3−4): 327−337.
- Norgaard JM., Olesen G., Kristensen J.S., Pedersen B., Hokland P. Leukaemia cell drug resistance and prognostic factors in AML. Eur J Haematol 1999- 63(4): 219−224.
- Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 1960−132: 1497−1501.
- Nussler V., Pelka-Fleisher R., Zwierzina H. et al. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes first experience with their reversal. Ann. Hematol., 1994- 69- Suppl. l: 2529.
- Pieters R., Huismans D.R., Leyva A., Veerman A.J.P. Adaptation of a rapid automated tetrazolium based (MTT)-assay for chemosensitivity testing in childhood leukemia. Cancer Lett., 1988- 41: 323−332.
- Pieters R., Huismans D.R., Loonen A.H., Hahlen K., van der Does-van den Berg A., van Wering E.R., Veerman A.J.P. Relation of cellular drug resistance to long-term outcome in childhood acute lymphoblastic leukemia. Lancet 1991- 338: 399−401.
- Pieters R., Kaspers G.J.L., Veerman A.J.P. Clinical resistance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art. Medical and Pediatric Oncology, 1994- 22: 299−308.
- Pirker R., Coldstein L.J., Ludwog H., Linkesch W., Lechner C., Gottesman M.M., Pastan I. Expression of a multidrug resistance gene in blast crisis of chronic myelogenous leukemia. Cancer Communications, 1989- 1: 141 144.
- Preisler H.D., Raza A., Gopal V. Predictive assays in acute leukemia. In Drug Resistance in Leukemia and Lymphoma I, 1993, 17−32, Harwood Acad. Publ., UK.
- Preisler H.D., Raza A., Larson R., Goldberg J., Tricot G., Carey M., Kukla
- C. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia. Leuk.Res., 1991- 15: 773−780.
- Preudhomme C., Dervite I., Wattel E., Vanrumbeke M., Flactif M., Lai J.L. Clinical significance of p53 mutations in newly diagnosed Burkitt’s lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J. Clin. Oncjl. 1995- 13: 812−820.
- Przepiorka D., Thomas E.D. Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia. Bone Marrow Transplant 1988, Mar- 3(2): 113−119.
- Rodriguez-Monge E.J., Cortes J.E., O’Brien S., Talpaz M., Kantarjian H.M. Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. Cancer 1997- 80(3): 396−400).
- Roger R., Isaad C., Pallardy M., Leglise M.-C., Turhan A.G., Bertoglio J., Breard J. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine activated killer cells. Blood 1996- 87: 11 131 122.
- Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quantative fluorescence and Giemsa staining. Nature 1973- 243: 290−293.
- Salmon S.E., Hamburger A.W., Soehlen B., Durie B.G.M., Alberts D.S., Moon T.E. Quantification of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 1978- 298: 1321−1327.
- Sargent J.M., Taylor C.G. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukemia. Br J Cancer 1989- 60: 206 210.
- Sawyers C.L. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Semin Hematol 2001- Vol.38, No.3, suppl. l: 15−21.
- Selby B., Buick R.N., Tannock I. A critical appraisal of the «human tumor stem-cell assay». N Engl J Med 1983- 308: 129−134.
- Sengelov L., Horn T., Steven K. p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J. Cancer Res. Clin. Oncol. 1997- 123: 565−570.
- Sjorgen S., Inganas M., Norberg T., Lindgren A., Nordgren H., Holmberg L. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistichemistry. J Natl Cancer Inst 1996- 88:173.182.
- Staib P., Schinkothl T., Henrichs R., Siebert T., Schoch C., Reiser M., Voliotis D., Lathan B., Diehl V. Prognostic value of in vitro drug sensitivity testing in adult AML. Leukemia 2001- Vol.15 No.3: abstr 44.
- Stavrovskaya A., Turkina A., Sedyakhina N., Stromskaya T., Zabotina T., Khoroshko N., Baryshnikov A. Prognostic value of P-glycoprotein and leucocyte differentiation antigens in chronic myeloid leukemia. Leuk Lymph 1998- Vol.28: 469−482.
- Stute N., Kohler T., Lehmann L., Wetzstein W., Ehnonger G. Drug resistance testing of acute myeloid leukemia in adults using the MTT assay. Adv Exp Med Biol 1999- 457: 445−452.
- Tamura K. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. Semin Hematol 1996- 33 (4 suppl3): 2−11.
- Tedeschi A., Montillo M., Ferrara F., Nosari A., Meie G., Copia C., Leoni P., Morra E. Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG). Eur J Haematol 2000- 64(3): 182−187.
- Thiebaut F., Tsuruo T., Hamada H. Cellular localisation of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc.Nat.Acad.Sci USA, 1987- 84: 7735−7738.
- Thiesing J.T., Ohno-Jones S., Kolibaba K.S., Druker B.J. Efficacy of an ABL-tyrosine kinase inhibitor in conjunction with other anti-leukemic agents against BCR-ABLpositive cells. Blood 2000- 96 (9): 3195−3199.
- Thiesing J.T., Ohno-Jones S., Kolibaba K.S., Druker B.J. Efficacy of an ABL-tyrosine kinase inhibitor in conjunction with other anti-leukemic agents against BCR-ABLpositive cells. Blood 2000- 96 (9): 3195−3199.
- Topaly J., Zeller W.J., Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001- 15: 342−347.
- Twentyman P.R. Drug resistance assays in leukemias and lymphomas. In Drug Resistance in Leukemia and Lymphoma I, 1993, 1−15, Harwood Acad. Publ., UK.
- Vaughan W.P., Karp J.E., Burke P.J. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 1984- 64: 975−978.
- Wadhwa J., Szydlo R.M., Apperley J.F., Chase A., Bua M., Marin D.,
- Olavarria E., Kanfer E., Goldman J.M. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002- vol.99, no.7: pp.2304 2309.
- Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994- 369: 574−578.
- Waldman T., Zhang Y., Dillehay L., Yu J., Kinzler K., Vogelstein B. Cell-cycle arrest versus cell death in cancer therapy. Nature Med. 1997- 3: 10 341 036.
- Wallace-Brodeur R.R., Lowe S.W. Clinical implications of p53 mutations. Cell Mol Life Sci 1999- 54: 64−75.
- Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I. P53 mutations are associated with resistance to chemotherapy and short survival in hematological malignancies. Blood 1994- 84: 31 483 157.
- Wei L.Y., Roepe P.D. Low external pH and osmotic shock increase the expression of human mdr protein. Biochemistry, 1994- 33: 7229−7232.
- Weisberg E., Griffin J.D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood2000- Vol.95, N. ll: 3498−3505.
- Weisenthal L., Marsden J.A., Dill P.L., Macaluso C.K. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 1983- 43: 749−757.
- Weisenthal L.M. Cell culture drug resistance assays in hematologic neoplasms based on the concept of total tumor cell kill. In Drug Resistance in Leukemia and Lymphoma I, 1993,415−432, Harwood Acad. Publ., UK.
- Weisenthal L.M., Lippman M.E. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 1985- 69: 615−632.
- Wilson W.H., Teruya-Feldstein J., Fest Т., Harris C., Steinberg S.M., Jaffe E.S. Relationship of p53, bcl-2 and tumour proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997- 89: 601−609.
- Wu S.Q., Voelkerding K.V., Sabatini L., Chen X.R., Huang J., Meisner L.F. Extensive amplification of bcr-abl fusion genes clustered on the three marker chromosomes in human leukemic cell line K-562. Leukemia 1995- 9: 858.
- Xia F., Wang X., Wang Y.H., Tsang N.M., Yandell D.W., Kelsey K.T. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 1995- 55:12−15.
- Zhou M., Yeager A.M., Smith S.D., Findley H.W. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995- 85: 1608−1614.
- А.Г.Туркина. Клиническое значение генетических и иммунофенотипических характеристик хронического миелолейкоза. Автореф. докт.дис. М., 1998 г.
- Бартащук Е.И. Властная трансформация хронического миелолейкоза (клшшко-цитологические исследования). Автореф. канд. лис., М., 1971, с. 16.
- Волкова М.А. Хронический миелолейкоз. В кн. Клиническая онкогематология. Под ред. М. А. Волковой. М., Медицина, 2001, с.237−262.
- Воробьев А.И. «Хронический миелолейкоз». В кн. Руководство по гематологии. М., Ньюдиамед, 2002, с.147 150.
- Гланц С. Медико-биологическая статистика. М., «Практика», 1999: с.327 332.
- Гланц С. Медико-биологическая статистика. М., «Практика», 1999: с.81 112.
- Зборовская И.Б. Супрессоры опухолевого роста (антионкогены), механизмы действия, участие в развитии гемобластозов. В кн. Клиническая онкогематология. Под ред. М. А. Волковой. М., Медицина, 2001, с.29−35.
- Карпова С.И., Тюрина Н. Г. Р-гликопротеин структура, функции и роль в резистентности лейкозов к химиотерапии. Проблемы гематологии и переливания крови 1997, 1: 37−46.
- Кассирский И.А. «Хронический миелолейкоз». В кн. Кассирского И. А. и Алексеева Т. А. Клиническая гематология. М., Медицина, 1970, с.380 390.
- Кременецкая О.С. Автореф. Канд. Дис.
- Михайлова И.Н. Клинико-иммунофенотипическая характеристика бластного криза хронического миелолейкоза. Автореф. канд. дис. Москва, 1995 г.
- Н.П.Логачева. Нестабильность иммунологического фенотипа бластных клеток при хроническом миелолейкозе. Автореф.канд.дис. Москва, 1998 г.
- Соколов А.Н., Савченко В. Г., Паровичникова E.H. Лечение резистентных форм острых лейкозов. Проблемы гематологии и переливания крови 1996, 4: 5−17.
- Ставровская A.A., Стромская Т. П., Штиль A.A. Генетические механизмы и закономерности развития множественной лекарственной устойчивости опухолевых клеток. Вестник ОНЦ- 1993, п. З, с. 37 — 47.
- Стюф И.Ю., Быкова Т. В., Зарицкий А. Ю., Фролова О. И., Маринец О. В., Афанасьев Б. В. Гиперэкспрессия гена множественной лекарственной устойчивости (М1Ж-1) у больных хроническим миелолейкозом. Тер.Арх. 1998- 70: 26−29.